The Paradigm Shift To Continuous Flow Processes: A Holistic View

The need for continuous flow manufacturing of active pharmaceutical ingredients and fine chemicals continues to grow, as it offers a number of important advantages over traditional batch manufacturing in terms of quality, safety, and sustainability of the overall process.

For pharmaceutical companies looking to optimize their own manufacturing, finding a contract development and manufacturing organization (CDMO) capable of operating continuous flow processes at commercial scales is paramount to cementing their competitive advantage in the market. To do so requires identifying partners with the expertise, assets, and skills to transition batch processing to continuous flow, scale up dangerous chemistries, and optimize recycling and waste management.

In a recent webinar, “The Paradigm Shift to Continuous Flow Processes: A Holistic View,” Dr. Bert Metten, Technology Development Manager at Ajinomoto Bio-Pharma Services, explored Aji Bio-Pharma’s proven expertise and capabilities in handling dangerous chemistries. Expertise in dangerous chemistries and continuous flow processes is crucial to ensuring the manufacture of safe, efficacious products while also delivering ecological benefits and cost savings.

A case study demonstrates experience with challenging chemistries related to scale-up using diazomethane, an extremely sensitive and volatile chemical used in producing the precursor for a client’s cyclopropanated product.